New study aims to crack the code of treatment resistance in lymphoma
NCT ID NCT07614035
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are receiving bispecific antibody therapy. Researchers want to understand why some patients don't respond or develop serious side effects. They will look at tumor samples, gut bacteria, and PET scans to find clues that could predict treatment success or failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bispecific antibodies (glofitamab, epcoritamab, mosunetuzumab)
What this could lead to
If successful, this could help doctors choose the best treatment for each patient and identify who might benefit most from bispecific antibody therapy.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Policlinico di Sant'Orsola
Bologna, Emilia-Romagna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••